All In Biotech

Drug Trial Radar · NCT05637255

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

99

Actual

Start

Nov 22, 2022

Primary completion

Dec 19, 2024

Study completion Dec 19, 2024

Sponsor

Lead sponsor
Sylentis, S.A.Industry
Sponsor type
Industry
First posted
Dec 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

Conditions

  • Wet Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Macular Degeneration

Interventions

  • SYL1801Drug

    1 drop in the eligible eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline on visual acuity on Day 42 after last instillation of the assigned dose levelTime frame: 42 days after first administration

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • SYL1801 Investigative Site

    Brno, Czechia

  • SYL1801 Investigative Site

    Chomutov, Czechia

  • SYL1801 Investigative Site

    Frýdek-Místek, Czechia

  • SYL1801 Investigative Site

    Kyjov, Czechia

  • SYL1801 Investigative Site

    Liberec, Czechia

  • SYL1801 Investigative Site

    Ostrava, Czechia

  • SYL1801 Investigative Site

    Prague, Czechia

  • SYL1801 Investigative Site

    Prague, Czechia

  • SYL1801 Investigative Site

    Gdansk, Poland

  • SYL1801 Investigative Site

    Krakow, Poland

  • SYL1801 Investigative Site

    Rzeszów, Poland

  • SYL1801 Investigative Site

    Warsaw, Poland

  • SYL1801 Investigative Site

    Bratislava, Slovakia

  • SYL1801 Investigative Site

    Košice, Slovakia

  • SYL1801 Investigative Site

    Poprad, Slovakia

  • SYL1801 Investigative Site

    Žilina, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.